Early Drug Development: From a Drug Candidate to the Clinic

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Early Drug Development

• Publication date

  2018-08-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/9783527801756.CH12
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Considerations for the development of in vitro dissolution tests to reduce or replace preclinical oral absorption studies

  2017cited by this paper
• Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.

  2015cited by this paper
• In vitro dissolution-permeation evaluation of an electrospun cyclodextrin-based formulation of aripiprazole using μFlux™.

  2015cited by this paper
• A randomized, open‐label 3‐way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20 mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20 mg tablets in healthy volunteers under fasting conditions

  2015cited by this paper
• Mechanism for enhanced absorption of a solid dispersion formulation of LY2300559 using the artificial stomach duodenum model.

  2015cited by this paper
• Extemporaneously prepared controlled release formulations for accelerating the early phase development of drug candidates.

  2014cited by this paper
• Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.

  2014cited by this paper
• In vitro models for the prediction of in vivo performance of oral dosage forms.

  2014cited by this paper
• Preclinical Formulations: Insight, Strategies, and Practical Considerations

  2014cited by this paper
• Application of COSMO-RS as an excipient ranking tool in early formulation development.

  2013cited by this paper
• Identification of suitable formulations for high dose oral studies in rats using in vitro solubility measurements, the maximum absorbable dose model, and historical data sets.

  2012cited by this paper
• A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept

  2012cited by this paper
• Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.

  2012cited by this paper
• Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.

  2011cited by this paper
• Recent advances and novel strategies in pre-clinical formulation development: an overview.

  2011cited by this paper
• Strategies for bringing drug delivery tools into discovery.

  2011cited by this paper
• The Manufacture of Low-Dose Oral Solid Dosage Form to Support Early Clinical Studies Using an Automated Micro-Filing System

  2011cited by this paper
• Effect of gastric pH on the pharmacokinetics of a BCS class II compound in dogs: utilization of an artificial stomach and duodenum dissolution model and GastroPlus,™ simulations to predict absorption.

  2011cited by this paper
• Relative bioavailability of three different solid forms of PNU-141659 as determined with the artificial stomach-duodenum model.

  2010cited by this paper
• Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.

  2010cited by this paper
• Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System.

  2010cited by this paper
• Use of artificial stomach-duodenum model for investigation of dosing fluid effect on clinical trial variability.

  2010cited by this paper
• The developability classification system: application of biopharmaceutics concepts to formulation development.

  2010cited by this paper
• Development and application of a high-throughput formulation screening strategy for oral administration in drug discovery.

  2010cited by this paper
• Dynamic dissolution: a step closer to predictive dissolution testing?

  2010cited by this paper
• IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.

  2009cited by this paper
• Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates.

  2009cited by this paper
• The State of Innovation in Drug Development

  2008cited by this paper
• Use of the Biopharmaceutical Classification System in Early Drug Development

  2008cited by this paper
• Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in‐vivo experiments

  2008cited by this paper
• Recent Options for Phase 1 Formulation Development and Clinical Trial Material Supply

  2008cited by this paper
• Developing early formulations: practice and perspective.

  2007cited by this paper
• Model behaviour

  2007cited by this paper
• Essentials of validation. Part II

  2006cited by this paper
• Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model.

  2006cited by this paper
• Preclinical formulations for discovery and toxicology: physicochemical challenges

  2006cited by this paper
• Enhancement of xcelodose capsule-filling capabilities using roller compaction

  2006cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Nanosuspensions in drug delivery

  2004cited by this paper
• Application of formulation technologies in lead candidate selection and optimization

  2004cited by this paper
• Pharmaceutical evaluation of early development candidates "the 100 mg-approach".

  2004cited by this paper
• Reducing the time to develop and manufacture formulations forfirst oral dose in humans

  2003cited by this paper
• In Vitro System to Evaluate Oral Absorption of Poorly Water-Soluble Drugs: Simultaneous Analysis on Dissolution and Permeation of Drugs

  2003cited by this paper
• Biorelevant Dissolution Testing to Predict the Plasma Profile of Lipophilic Drugs After Oral Administration

  2001cited by this paper
• WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI: Ethical Principles for Medical Research Involving Human Subjects

  2001cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Feasibility Assessment and Rapid Development of Oral Controlled Release Prototypes

  2000cited by this paper
• Drug interactions with diosmectite: a study using the artificial stomach-duodenum model.

  1999cited by this paper
• A computerized artificial stomach model to assess sodium alginate-induced pH gradient

  1998cited by this paper
• Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs

  1998cited by this paper
• A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability

  1995cited by this paper
• The stability of intravenous fat emulsions in total parenteral nutrition mixtures

  1990cited by this paper
• Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells.

  1990cited by this paper

• No citing papers are available for this paper.